Liege, Belgium — October 7, 2025 — Leads & Copy — Allegro NV announced new research demonstrating superior shock-absorbing capacities of its Hydrocelin injectable hydrogel for osteoarthritis treatment, compared to four market-leading hydrogels. The company presented the results in a poster at the CellMech conference in Louvain, Belgium, last week. The results also showed that Hydrocelin significantly improved the shock-absorbing properties of pathological equine synovial fluid in mechanical testing.
According to Lucas Decuypere, Chief Executive Officer at Allegro, the data provide robust support for Hydrocelin’s revolutionary potential as a responsive hydrogel designed to restore joint shock-absorbing capacities.
The data revealed that Hydrocelin’s shock-absorbing capacity surpassed that of four commonly used hydrogels, and pathological synovial fluid from horses materially improved its shock-absorbing profile when Hydrocelin was added. The company plans to submit the data to a peer-reviewed journal for publication.
Allegro’s hydrocelin contains cross-linked particles designed to act as tiny shock absorbers in the synovial fluid of joints. Restoring the shock-absorbing capacity of the synovial fluid is intended to provide pain relief and protect cartilage. Hydrocelin is designed to be the first non-invasive disease-modifying treatment for use in osteoarthritis, expected to be administered by annual injection into the joint.
In April, Allegro presented positive preclinical data demonstrating the satisfactory safety profile of hydrocelin at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO) in Rome. In addition to this pyrogenicity study, the company has also demonstrated a satisfactory safety profile in preclinical studies assessing irritation, delayed sensitization and systemic toxicity.
Lucas Decuypere, Chief Executive Officer, info@allegro.bio
Mary-Ann Chang, Cohesion Bureau, +44 7483 284 853, mary-ann.chang@cohesionbureau.com
Douwe Miedema, Cohesion Bureau, +352 621 562 764, douwe.miedema@cohesionbureau.com
Source: Allegro NV
